Editor's note: Seeking Alpha is proud to welcome Biotech Fan as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click
Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Summary
- Albireo developed Odevixibat- a product as a pipeline - as a life-saving therapy for multiple ultra-rare pediatric liver disease indications.
- The market potential is in the billions and well reachable with the announced positive Phase 3 results and PDUFA date set on 21 July.
- Launch of Odevixibat and sale of the Priority Review Voucher to strengthen the cash position is planned in the second half of 2021.
- Albireo is in the leadership role within the market and can successfully differentiate itself from competition to achieve a high penetration in the limited market.
- The share has the chance to become a ten-bagger with acceptable downside from current levels.
Hey there, I would like to encourage you to follow me and read my articles for stocks with an excellent risk-reward profile. i am an individual who enjoys dealing with public Biotech companys. I write articles not for investment activities, I just want to share my knowledge gained through the researches for stocks in my own Portfolio.
Analyst’s Disclosure:I am/we are long ALBO. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.